Clinical Trial

Comparison of Liver Biopsy Versus Fibroscan With CAP ( Controlled Attenuation Parameter) in Donors Evaluation for Liver Transplant

Study acronym: DonorFibroScan
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
In our study we aiming that liver biopsy histological analysis as a reference standard, to examine the precision of fbroscan controlled attenuation parameter (CAP) for quantitative evaluation of macrovesicular steatosis in living related liver donors.
Trial Details
NCT Number NCT07451379
Lead Sponsor Assiut University
Conditions Non-invasive Donor Liver Assessment
Enrollment 100 participants
Start Date 2026-07-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-05